CN1634118A - Antivirus formulation containing polysaccharide polyanion zinc salt and its preparing process - Google Patents
Antivirus formulation containing polysaccharide polyanion zinc salt and its preparing process Download PDFInfo
- Publication number
- CN1634118A CN1634118A CN 200410036061 CN200410036061A CN1634118A CN 1634118 A CN1634118 A CN 1634118A CN 200410036061 CN200410036061 CN 200410036061 CN 200410036061 A CN200410036061 A CN 200410036061A CN 1634118 A CN1634118 A CN 1634118A
- Authority
- CN
- China
- Prior art keywords
- zinc salt
- polysaccharide
- polyanion
- preparation
- weight ratio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention provides an antivirus formulation containing polysaccharide polyanion zinc salt and its preparing process, wherein the polysaccharide polyanion zinc salt comprises natural or artificially modified or/and cross-linked hyaluronic acid, chondroitin sulfate, heparins, alginic acids, xanthans, and zinc salts of glucans. The formulation comprises 0.1-10 wt% of polysaccharides compound zinc salts, 0-0.1 wt% of antihistamine drugs, 0-1 wt% of vasoconstriction medicine, 0-5 wt% of antipyretic analgesic, 0-2 wt% of cough suppressants, 0-1 wt% of traditional Chinese medicinal extract for heat clearing and detoxicating.
Description
Technical field:
The present invention relates to a kind of polysaccharide polyanion zinc salt that contains and prepare anti-virus formulation and preparation method thereof, belong to medical technical field.
Background technology:
It is well-known that the zinc agent can prevent and treat flu, the 60%-70% flu is caused by rhinovirus, the seventies in last century, U.S. Du Pont seminar spent for five years, screened 12 metal ion species such as cadmium, ingot, cobalt, copper, magnesium, manganese, hydrargyrum, molybdenum, nickel and zinc, observed effect different picornaviruss.The result shows Zn
2+To 8 kinds among 9 kinds of human rhinovirus direct killing action is arranged at non-toxic concn (0.1mM).In addition, Zn
2+To other virus as: but herpes simplex virus, influenza virus Sa Qi virus and small nut virus etc. all have inhibitory action.Zn
2+Also can stimulate interferon when directly suppressing virus and bring into play the efficient disease-resistance toxic action.Studies confirm that Zn
2+Human lymphocyte there are mitosis promoting effect, Zn
2+Concentration can induce a large amount of gamma interferons when 0.05-0.5mM.Zn
2+Cell membrane has direct protection and Stabilization, can prevent the damage of Lysin at interior cell toxicant pair cell, and its intensity is equivalent to interferon.In vitro study shows, Zn
2+Can influence mastocyte.Equally, Zn
2+Effect prompting Zn to all mucosa-immune system cells
2+Has immunoregulation effect.Use Zn
2+During the treatment flu, along with stablizing of leukocyte, cell membrane and lysosome membrane, local inflammation disappears very soon.Oral a certain amount of compound of polysaccharide zinc salt can improve the Zn of each histoorgan after human body absorbs
2+Concentration increases the ability that human body is resisted virus, and the certain density compound of polysaccharide zinc salt of topical application can dissociate the zinc ion (Zn of valid density in the human body local organization
2+), pathogen virus played kill and inhibitory action.On the other hand, polyanionic polysaccharide has excellent biological compatibility, has no side effect, and it has certain viscosity, also has to preserve moisture, lubricate and antiinflammatory action in the external preparation, more helps the improvement of local symptom.The compound of polysaccharide zinc salt is compared with other zinc agent, advantage such as have prevention and therapeutic effect is good, the time is long, toxic and side effects is light, zest is little, local symptom alleviates soon.
Summary of the invention:
The anti-virus formulation that contains polysaccharide polyanion zinc salt of the present invention is characterized in that containing weight ratio 0.1%～100% compound of polysaccharide zinc salt; The antihistaminic of weight ratio 0～1% comprises chlorphenamine maleate, dioxopromethazine hydrochloride, terfenadine, promethazine, ketotifen fumarate, acrivastine, hydrochloric acid levocabastine, diphenhydramine, sodium cromoglicate, astemizole, clemastine fumarate, cetirizine hydrochloride and loratadine; Weight ratio 0～10% vasoconstrictor comprises ephedrine, pseudoephedrine hydrochloride, naphcon, oxymetazoline hydrochloride and hydrochloric acid plug Lip river azoles quinoline; The antipyretic analgesic of weight ratio 0～20% comprises acetaminophen, aspirin, ibuprofen, diclofenac sodium and taurine; Weight ratio 0～5% antitussive comprises dextromethorphan hydrobromide, codeine phosphate, caffeine, guaifenesin, Bisolvon and sulfogaiacol; The Chinese medicine extract of weight ratio 0～50% heat-clearing and toxic substances removing comprises the extract of Radix Isatidis, Radix Glycyrrhizae, Flos Lonicerae, Rhizoma Osmundae, artificial Calculus Bovis, Radix Scutellariae, Fructus Forsythiae, Folium Isatidis.
Tablet of the present invention, granule, capsule, in the 100g said preparation, it is made up of following component and consumption proportion scope: compound of polysaccharide zinc salt 1～100g, antihistaminic 0～1g, vasoconstrictor 0～10g, antipyretic analgesic 0～20g, antitussive 0～5g, the Chinese medicine extract 0～50g of heat-clearing and toxic substances removing, lactose 0～25g, sucrose 0～25g, starch 0～25g, calcium sulfate 0～3g, microcrystalline Cellulose 0～25g, micropowder silica gel 0～3g, tartaric acid 0～1g, magnesium stearate 0～1g.
Suppository of the present invention, in the 100g said preparation, it is made up of following component and consumption proportion scope: compound of polysaccharide zinc salt 1～100g, antipyretic analgesic 0～20g, Chinese medicine extract 0～the 50g of heat-clearing and toxic substances removing, parabens 0～0.25g, glycerin gelatine 0～90g, tween 0～5g, polyethylene glycols 0～60g, polyoxyethylene monostearate class 0～90g, glycerol 0～10g, all the other are distilled water.
Membrane of the present invention, in the 100g said preparation, it is made up of following component and consumption proportion scope: compound of polysaccharide zinc salt 1～100g, water-soluble cellulose 0～20g, polyvinyl alcohol 0～20g, sorbitol 0～25g tween 0～20g.
Oral solution of the present invention, suspensoid, Emulsion, in the 100g said preparation, it is made up of following component and consumption proportion scope: compound of polysaccharide zinc salt 0.1～10g, antihistaminic 0～0.1g, vasoconstrictor 0～1g, antipyretic analgesic 0～5g, antitussive 0～0.5g, Chinese medicine extract 0～the 5g of heat-clearing and toxic substances removing, benzoic acid or its sodium salt 0～0.3g, parabens 0～0.25g, sorbic acid 0～0.2g, arabic gum 0～15g, pectin 0～5g, sodium alginate 0～10g, gelatin 0～5g, syrup 0～80g, Oleum menthae 0～0.3g, all the other are distilled water.
Externally used solution agent of the present invention, suspensoid, gel, in the 100ml said preparation, it is made up of following component and consumption proportion scope: compound of polysaccharide zinc salt 0.1～10g, antihistaminic 0～0.1g, vasoconstrictor 0～1g, antipyretic analgesic 0～5g, antitussive 0～0.5g, the Chinese medicine extract 0～5g of heat-clearing and toxic substances removing, boric acid 0～1.9g, Borax 0～0.02g, citric acid 0～0.1g, sodium citrate 0～0.5g, acetic acid 0～0.1g, sodium acetate 0～0.3g, geramine class 0～0.5g, parabens 0～0.3g, potassium sorbate 0～0.2g, phenethanol 0～0.5g, chlorhexidine acetate 0～0.5g, triclosan 0～0.1g, disodiumedetate 0～0.2g, Tweens 0～0.5g, glycerol 0～3.0g, polyoxyethylene hydrogenated Oleum Ricini class 0～10g, triethanolamine 0～5g, glycerol 0～3.0g, water-soluble cellulose 0～5g, polyvidone class 0～10g, polyethylene glycols 0～5g, polyvinyl alcohol 0～5g, carbomer 0～5g, all the other are distilled water.
Ointment of the present invention, exterior-applied emulsion, in the 100ml said preparation, it is made up of following component and consumption proportion scope: compound of polysaccharide zinc salt 0.1～10g, antihistaminic 0～0.1g, vasoconstrictor 0～1g, antipyretic analgesic 0～5g, antitussive 0～0.5g, the Chinese medicine extract 0～5g of heat-clearing and toxic substances removing, propylene glycol 0～15g, glycerol 0～15g, vaseline 0～30g,, monoglyceride 0～10g, octadecanol 0～15g, paraffin oil 0～10g,, stearic acid 0～10g, lanoline 0～10g, tween 0～5g, span 0～5g, sodium lauryl sulphate 0～5g, arabic gum 0～15g, gelatin 0～5g, parabens 0～0.5g, all the other are distilled water.
The purpose of this invention is to provide and contain anti-virus formulation natural or deutero-polysaccharide polyanion zinc salt, this anti-virus formulation can be unique active component with polysaccharide polyanion zinc salt, also can with the Chinese medicine extract isoreactivity components matching prescription of antihistaminic, vasoconstrictor, antipyretic analgesic, antitussive, heat-clearing and toxic substances removing, can add proper auxiliary materials according to the preparation production technique of routine.Anti-virus formulation of the present invention can be a solid preparation, as granule, tablet, capsule, suppository and membrane etc., also can be semi-solid preparation, as gel and ointment etc., can also be liquid preparation, as solution, suspensoid, Emulsion etc.Anti-virus formulation of the present invention comprises oral formulations and external preparation, can be used for prevention and treatment viral influenza, also can be used for preventing and treating the local disease toxinfection of eye, skin, reproductive tract mucosa, have that side effect is light, zest is little, a prevention and therapeutic effect is good, the time long, local symptom alleviates advantages such as fast, easy to use.
The present invention contains anti-virus formulation natural or deutero-polysaccharide polyanion zinc salt.Wherein natural polysaccharide polyanion zinc salt is polysaccharide and Zn driven, plant extract
2+Salify or the zinc salt that obtains through ion exchange.Deutero-polysaccharide polyanion zinc salt is the polysaccharide that extracts based on animal and plant, through manually modified or/and after crosslinked, with Zn
2+Salify or the zinc salt that obtains through ion exchange.Described polysaccharide comprises hyalomitome acids, chondroitin sulfates, heparin class, Sargassum acids, xanthan gum class and glucan etc.
Anti-virus formulation of the present invention can be unique active component with one or more polysaccharide polyanion zinc salt, also can use one or more the polysaccharide polyanion zinc salt and the Chinese medicine extract isoreactivity components matching prescription of antihistaminic, vasoconstrictor, antipyretic analgesic, antitussive, heat-clearing and toxic substances removing.Antihistaminic wherein comprises chlorphenamine maleate, dioxopromethazine hydrochloride, terfenadine, promethazine, ketotifen fumarate, acrivastine, hydrochloric acid levocabastine, diphenhydramine, sodium cromoglicate, astemizole, clemastine fumarate, cetirizine hydrochloride and loratadine etc.Vasoconstrictor wherein comprises ephedrine, pseudoephedrine hydrochloride, naphcon, oxymetazoline hydrochloride and hydrochloric acid plug Lip river azoles quinoline etc.Antipyretic analgesic wherein comprises acetaminophen, aspirin, ibuprofen, diclofenac sodium and taurine.Antitussive wherein comprises dextromethorphan hydrobromide, codeine phosphate, caffeine, guaifenesin, Bisolvon and sulfogaiacol etc.The Chinese medicine extract of heat-clearing and toxic substances removing wherein comprises the extract of Chinese medicines such as Radix Isatidis, Radix Glycyrrhizae, Flos Lonicerae, Rhizoma Osmundae, artificial Calculus Bovis, Radix Scutellariae, Fructus Forsythiae, Folium Isatidis.
Anti-virus formulation of the present invention comprises solid preparation, semi-solid preparation and liquid preparation.Wherein solid preparation comprises granule, tablet, capsule, suppository and membrane etc., and semi-solid preparation comprises gel, ointment etc., and liquid preparation comprises solution, suspensoid, Emulsion etc.
Anti-virus formulation of the present invention comprises oral formulations and external preparation, wherein oral formulations can be solution, suspensoid, Emulsion, granule, tablet and capsule etc., and external preparation can be solution, suspensoid, Emulsion, gel, suppository, ointment and membrane etc.
Anti-virus formulation of the present invention can add proper excipient and adjuvant according to the production technology of different dosage form, comprises buffer agent, antiseptic, thickening agent, suspending agent, emulsifying agent, filler, adhesive, correctives and lubricant etc.Wherein buffer agent comprises boric acid and sodium salt, citric acid and sodium salt thereof, acetic acid and sodium salt thereof etc.Wherein antiseptic comprises geramine class, parabens, benzoic acid and sodium benzoate, sorbic acid and potassium salt thereof, phenethanol, chlorhexidine acetate, triclosan, disodiumedetate etc.Wherein emulsifying agent comprises tween, span, sodium lauryl sulphate, triethanolamine, polyoxyethylene hydrogenated Oleum Ricini class etc.Wherein suspending agent, adhesive and thickening agent comprise glycerol, arabic gum, gelatin, glycerin gelatine, pectin, sodium alginate, cellulose and derivant thereof, polyvidone class, polyethylene glycols, polyvinyl alcohol, carbomer, propylene glycol, vaseline, monoglyceride, octadecanol, paraffin oil, stearic acid and lanoline etc.Wherein filler comprises lactose, starch, microcrystalline Cellulose, tartaric acid, calcium phosphate etc.Wherein correctives comprises syrup, Herba Menthae wet goods.Wherein lubricant comprises magnesium stearate, micropowder silica gel and Pulvis Talci etc.
Anti-virus formulation of the present invention can be used for prevention and treatment viral influenza by oral and nasal cavity topical, also can be used to prevent and treat the local disease toxinfection of eye, skin, reproductive tract mucosa by oral drawn game portion topical administration.Wherein the preparation for the nasal cavity topical comprises solution, suspensoid, Emulsion and gel etc., preparation for the local skin administration comprises solution, suspensoid, Emulsion, gel, ointment etc., preparation for reproductive tract mucosa topical comprises gel, suppository, ointment and membrane etc., and the preparation that uses for eye comprises eye drop, eye suspensoid, gel for eye, Eye ointments etc.
The specific embodiment:
1. tablet of the present invention, in 100g dry powder, filling a prescription is Curiosin 70g, lactose 10g, microcrystalline Cellulose 20g after production technology is routinely made granule, is pressed into the slice, thin piece of 0.25g. or 0.5g.Behind the tabletting, for avoiding the moisture absorption, the colourless or colorful film clothing of outsourcing.
2. tablet of the present invention, in 100g dry powder, filling a prescription is Curiosin 14g, acetaminophen 10g, dioxopromethazine hydrochloride 0.1g, Radix Isatidis extract powder 25g, lactose 15g, starch 9g, calcium sulfate 1g, micropowder silica gel 1.5g, microcrystalline Cellulose 25g, tartaric acid 0.5g after production technology is routinely made granule, is pressed into the slice, thin piece of 0.5g.Behind the tabletting, for avoiding the moisture absorption, the colourless or colorful film clothing of outsourcing.
3. tablet of the present invention, with the 100g dry powder doses, filling a prescription is Curiosin 40g, ibuprofen 10g, chlorphenamine maleate 0.4g, lactose 10g, starch 10g, calcium sulfate 1.5g, micropowder silica gel 1g, microcrystalline Cellulose 25g, tartaric acid 0.5g, magnesium stearate 1.5g after production technology is routinely made granule, is pressed into the slice, thin piece of 0.5g.Behind the tabletting, for avoiding the moisture absorption, the colourless or colorful film clothing of outsourcing.
4. granule of the present invention, in the 100g said preparation, filling a prescription is Curiosin 10g, lactose 73g, calcium sulfate 1.5g, microcrystalline Cellulose 15g, tartaric acid 0.5g, production technology is routinely made the granule of certain particle size, is distributed into packed granule, every bag of 5g or 10g.
5. granule of the present invention, in the 100g said preparation, filling a prescription is Curiosin 5.7g, acetaminophen 4g, dioxopromethazine hydrochloride 0.04g, Radix Isatidis extract powder 10g, lactose 25g, sucrose 38g, calcium sulfate 1.5g, microcrystalline Cellulose 15g, tartaric acid 0.7g, production technology is routinely made the granule of certain particle size, is distributed into packed granule, every bag of 5g or 10g.
6. granule of the present invention, in the 100g said preparation, filling a prescription is Curiosin 4g, ibuprofen 1g, chlorphenamine maleate 0.04g, lactose 25g, sucrose 48g, calcium sulfate 1.5g, microcrystalline Cellulose 20g, tartaric acid 0.5g, production technology is routinely made the granule of certain particle size, be distributed into packed granule, every bag of 5g or 10g.
7. capsule of the present invention, in the 100g said preparation, filling a prescription is Curiosin 70g, lactose 20g, microcrystalline Cellulose 10g, production technology is routinely made the granule of certain particle size, divides to install in the hard capsule every 0.25g. or 0.5g.
8. capsule of the present invention, in the 100g said preparation, filling a prescription is Curiosin 15g, acetaminophen 32.5g, pseudoephedrine hydrochloride 3g, dextromethorphan hydrobromide 1.5g, lactose 25g, calcium sulfate 1.5g, microcrystalline Cellulose 20g, production technology is routinely made the granule of certain particle size, divides to install in the hard capsule every 0.25g. or 0.5g.
9. capsule of the present invention, in the 100g said preparation, Curiosin 35g, acetaminophen 50g, pseudoephedrine hydrochloride 2g, caffeine 1g, lactose 2g, calcium sulfate 1g, microcrystalline Cellulose 9g, production technology is routinely made the granule of certain particle size, divides to install in the hard capsule every 0.25g. or 0.5g.
10. suppository of the present invention, in the 100g said preparation, filling a prescription is Curiosin 10g, ethylparaben 0.1g, Tween 80 1g, glycerin gelatine 88.9g, production technology is routinely made suppository, and every piece weighs 2g or 4g.
11. suppository of the present invention, in the 100g said preparation, filling a prescription is Curiosin 15g, polyoxyethylene (40) monostearate esters 80g, glycerol 2.5g.Triclosan 0.01, polyoxyethylene hydrogenated Oleum Ricini 2g, production technology is routinely made suppository, and every piece weighs 0.5g or 1g.
12. suppository of the present invention, in the 100g said preparation, filling a prescription is Curiosin 15g, Macrogol 4000 22g, and polyethylene glycol 6000 31g, glycerol 5g, chlorhexidine acetate 0.05g, all the other are distilled water, and production technology is routinely made suppository, and every piece weighs 1g or 2g.
13. the invention membrane, in the 100g said preparation, filling a prescription is Curiosin 57g, polyvinyl alcohol 17-18 10g, and carboxymethyl cellulose 10g, sorbitol 13g, Tween 80 10g, production technology is routinely made 400cm
2Film, cut into 2cm
2Or 4cm
2The little lattice of single dose, be separated by with thin paper, convolution or bind into book form after be packaged into bag.
14. oral solution of the present invention, in the 100ml said preparation, filling a prescription is Curiosin 0.7g, sodium benzoate 0.1g, and gelatin 1g, syrup 1g, Oleum menthae 0.1g, all the other are distilled water, production method is made oral liquid routinely.
15. oral solution of the present invention, in the 100ml said preparation, filling a prescription is Curiosin 3.5g, Folium Isatidis extract 1g, and syrup 90g, polyethylene glycol 6000 1g, all the other are distilled water, production method is made oral liquid routinely.
16. oral suspensions of the present invention, in the 100ml said preparation, prescription is Curiosin 0.4g, ibuprofen 0.1g, chlorphenamine maleate 0.004g, sodium alginate 3.5g, ethylparaben 0.05g, propyl p-hydroxybenzoate 0.05g, Tween 80 1g, all the other are distilled water, and production method is made oral liquid routinely.
17. Orally taken emulsion of the present invention, in the 100ml said preparation, filling a prescription is Curiosin 7g, acetaminophen 0.5g, dioxopromethazine hydrochloride 0.005g, Radix Isatidis extract powder 1.25g, sorbic acid 1g, pectin 1g, arabic gum 5g, syrup 1g, Oleum menthae 0.1g, all the other are distilled water, and production method is made oral liquid routinely.
18. externally used solution agent of the present invention, wherein, wherein in 100ml, it is made up of following component and consumption proportion: Curiosin 3.5g, citric acid monohydrate 0.03g, Sodium Citrate, usp, Dihydrate Powder 0.25g, ethylparaben 0.01g, glycerol 2.6g, all the other are distilled water, production method is made eye drop, nasal drop or washing liquid routinely.
19. external suspensoid of the present invention, wherein in 100ml, it is made up of following component and consumption proportion: Curiosin 1.5g, acetaminophen 3.25g, pseudoephedrine hydrochloride 0.3g, dextromethorphan hydrobromide 0.15g, acetic acid 0.01g, sodium acetate 0.09g, potassium sorbate 0.05g, Tween 80 0.05g, polyvidone k90 2g, all the other are distilled water, and production method is made nasal drop routinely.
20. external suspensoid of the present invention, wherein in 100ml, it is made up of following component and consumption proportion: Curiosin 1.5g, pseudoephedrine hydrochloride 0.3g, dextromethorphan hydrobromide 0.15g, guaifenesin 1g, boric acid 1.6g, Borax 0.02g, chlorhexidine acetate 0.05g, Tween 80 0.15g, hydroxypropyl methylcellulose 2g, all the other are distilled water, and production method is made nasal drop routinely.
21. external suspensoid of the present invention, wherein in 100ml, it is made up of following component and consumption proportion: Curiosin 1.5g, promethazine hydrochloride 0.08g, codeine phosphate 0.1g, ephedrine hydrochloride 0.1g, sulfogaiacol 1g, boric acid 1.6g, Borax 0.02g, chlorhexidine acetate 0.05g, Tween 80 0.15g, hydroxypropyl methylcellulose 2g, all the other are distilled water, production method is made nasal drop routinely.
22. external suspensoid of the present invention, wherein in 100g, it is made up of following component and consumption proportion: Curiosin 1.9g, ibuprofen 1.5g, chlorphenamine 0.02g, acetic acid 0.01g, sodium acetate 0.09g, disodiumedetate 0.02g, potassium sorbate 0.05g, Tween 80 0.05g, polyvidone k90 2g, all the other are distilled water, and production method is made nasal drop routinely.
23. exterior-applied emulsion of the present invention, in the 100g said preparation, filling a prescription is Curiosin 3.5g, stearic acid 6g, and octadecanol 4g, monoglyceride 2g, sorbester p17 1.2g, tween 5g, bromo geramine 0.05g, all the other are distilled water, production method is made the external emulsion routinely.
24. ointment of the present invention, in the 100g said preparation, filling a prescription is Curiosin 3.5g, stearic acid 10g, monoglyceride 4g, octadecanol 3g, white vaseline 12g, liquid Paraffin 8g, glycerol 12g, sodium lauryl sulphate 1g, ethyl hydroxybenzoate 0.1g, all the other are distilled water, and production method is made ointment routinely.
25. gel of the present invention, in the 100g said preparation, filling a prescription is Curiosin 0.62g, acetaminophen 1.5g, dioxopromethazine hydrochloride 0.005g, Radix Isatidis dipping cream 1.25g, boric acid 1.6g, Borax 0.01g, bromo geramine class 0.01g, disodiumedetate 0.01g, Tween 80 0.05g, hydroxypropyl methylcellulose 2g, all the other are distilled water, production method is made gel routinely.
26. gel of the present invention, in the 100g said preparation, filling a prescription is Curiosin 2.5g, acetaminophen 1.2g, chlorphenamine maleate 0.02g, Radix Glycyrrhizae extractum 1g, triclosan 0.01, polyoxyethylene hydrogenated Oleum Ricini 2g, glycerol 2.5g, triethanolamine 1g, carbomer 1g, all the other are distilled water, and production method is made gel routinely.
27. gel of the present invention, in the 100g said preparation, filling a prescription is Curiosin 3.5g, acetaminophen 5.0g, pseudoephedrine hydrochloride 0.2g, caffeine 0.1g, citric acid monohydrate 0.03g, Sodium Citrate, usp, Dihydrate Powder 0.27g, methyl parahydroxybenzoate 0.011g, propyl p-hydroxybenzoate 0.002g, polyethylene glycol 6000 1g, all the other are distilled water, and production method is made gel routinely.
28. gel of the present invention, in the 100g said preparation, filling a prescription is Curiosin 2.5g, acetaminophen 3.25g, pseudoephedrine hydrochloride 0.3g, chlorphenamine 0.02g, citric acid monohydrate 0.03g, Sodium Citrate, usp, Dihydrate Powder 0.25g, methyl parahydroxybenzoate 0.011g, propyl p-hydroxybenzoate 0.002g, polyethylene glycol 6000 2g, all the other are distilled water, and production method is made gel routinely.
29. gel of the present invention, in the 100g said preparation, filling a prescription is Curiosin 1.5g, acetaminophen 1.62g, pseudoephedrine hydrochloride 0.15g, Fei Tenading 0.15g, citric acid monohydrate 0.03g, Sodium Citrate, usp, Dihydrate Powder 0.26g, bromo geramine 0.01g, disodiumedetate 0.01g, Tween 80 0.05g, hydroxypropyl methylcellulose 2g, all the other are distilled water, production method is made gel routinely.
30. gel of the present invention, in the 100g said preparation, filling a prescription is Curiosin 2.5g, acetaminophen 3.25g, pseudoephedrine hydrochloride 0.3g, dextromethorphan hydrobromide 0.15g, chlorphenamine maleate 0.02g, citric acid monohydrate 0.03g, Sodium Citrate, usp, Dihydrate Powder 0.27g, triclosan 0.01, polyoxyethylene hydrogenated Oleum Ricini 2g, glycerol 2.5g, carbomer 1.2g, all the other are distilled water, and production method is made gel routinely.
31. gel of the present invention, in the 100g said preparation, filling a prescription is Curiosin 1.5g; acetaminophen 2.5g, chlorphenamine 0.02g, caffeine 0.15g; artificial Calculus Bovis 0.1g, citric acid monohydrate 0.03g, Sodium Citrate, usp, Dihydrate Powder 0.25g; methyl parahydroxybenzoate 0.011g, propyl p-hydroxybenzoate 0.002g, Tween 80 0.25g; glycerol 2g, triethanolamine 1g, carbomer 1g; all the other are distilled water, and production method is made gel routinely.
32. gel of the present invention, in the 100g said preparation, filling a prescription is Curiosin 2.5g; acetaminophen 0.75g; chlorphenamine 0.01g, artificial Calculus Bovis 0.045g, Tween 80 0.25g; ethylparaben 0.05g; glycerol 2g, triethanolamine 1g, carbomer 1g; all the other are distilled water, and production method is made gel routinely.
33. gel of the present invention, in the 100g said preparation, filling a prescription is Curiosin 3.5g, Flos Lonicerae extract 1.5g, Rhizoma Osmundae extract 1g, citric acid monohydrate 0.03g, Sodium Citrate, usp, Dihydrate Powder 0.25g, methyl parahydroxybenzoate 0.011g, propyl p-hydroxybenzoate 0.002g, Tween 80 0.15g, hydroxypropyl methylcellulose 1g, all the other are distilled water, and production method is made gel routinely.
34. gel of the present invention, in the 100g said preparation, prescription is Curiosin 2.5g, aspirin 2g, citric acid monohydrate 0.03g, Sodium Citrate, usp, Dihydrate Powder 0.25g, methyl parahydroxybenzoate 0.011g, propyl p-hydroxybenzoate 0.002g, polyethylene glycol 6000 2g, all the other are distilled water, and production method is made gel routinely.
35. gel of the present invention, in the 100g said preparation, filling a prescription is Curiosin 3.5g, Fructus Forsythiae extract 1g, Flos Lonicerae extract 0.5g, Radix Scutellariae extract 0.5g, citric acid monohydrate 0.03g, Sodium Citrate, usp, Dihydrate Powder 0.25g, methyl parahydroxybenzoate 0.011g, propyl p-hydroxybenzoate 0.002g, polyvinyl alcohol 1g, all the other are distilled water, and production method is made gel routinely.
36. gel of the present invention, in the 100g said preparation, filling a prescription is Curiosin 2.5g, acetaminophen 3.25g, pseudoephedrine hydrochloride 0.3g, dextromethorphan hydrobromide 0.15g, diphenhydramine 0.25g, citric acid monohydrate 0.03g, Sodium Citrate, usp, Dihydrate Powder 0.26g, methyl parahydroxybenzoate 0.011g, propyl p-hydroxybenzoate 0.002g, polyethylene glycol 6000 2g, all the other are distilled water, production method is made gel routinely.
37. gel of the present invention, in the 100g said preparation, filling a prescription is Curiosin 3.5g, triclosan 0.01, and polyoxyethylene hydrogenated Oleum Ricini 2g, propylene glycol 8.5g, triethanolamine 1g, carbomer 1g, all the other are distilled water, production method is made gel routinely.
Claims (6)
1. one kind by oral or skin, mucosa delivery, be used to prevent and treat the anti-virus formulation of viral influenza or prevention and treatment eye, skin, reproductive tract mucosa local disease toxinfection, it is characterized in that containing natural or deutero-polysaccharide polyanion zinc salt.
2. the described anti-virus formulation of claim 1 is characterized in that containing weight ratio 0.1%～100% compound of polysaccharide zinc salt; The antihistaminic of weight ratio 0～1% comprises chlorphenamine maleate, dioxopromethazine hydrochloride, terfenadine, promethazine, ketotifen fumarate, acrivastine, hydrochloric acid levocabastine, diphenhydramine, sodium cromoglicate, astemizole, clemastine fumarate, cetirizine hydrochloride and loratadine; Weight ratio 0～10% vasoconstrictor comprises ephedrine, pseudoephedrine hydrochloride, naphcon, oxymetazoline hydrochloride and hydrochloric acid plug Lip river azoles quinoline; The antipyretic analgesic of weight ratio 0～20% comprises acetaminophen, aspirin, ibuprofen, diclofenac sodium and taurine; Weight ratio 0～5% antitussive comprises dextromethorphan hydrobromide, codeine phosphate, caffeine, guaifenesin, Bisolvon and sulfogaiacol; The Chinese medicine extract of weight ratio 0～50% heat-clearing and toxic substances removing comprises the extract of Radix Isatidis, Radix Glycyrrhizae, Flos Lonicerae, Rhizoma Osmundae, artificial Calculus Bovis, Radix Scutellariae, Fructus Forsythiae, Folium Isatidis.
3. the described natural polysaccharide polyanion zinc salt of claim 1 is characterized in that comprising the zinc salt of hyalomitome acids, chondroitin sulfates, heparin class, Sargassum acids, xanthan gum class and glucan.
4. the described deutero-polysaccharide polyanion zinc salt of claim 1 is characterized in that comprising manually modified or/and the zinc salt of crosslinked hyalomitome acids, chondroitin sulfates, heparin class, Sargassum acids, xanthan gum class and glucan.
5. the described anti-virus formulation of claim 1 is characterized in that route of administration is oral, eye and nasal cavity local topical, skin and reproductive tract mucosa local topical.
6. the described anti-virus formulation of claim 1 is characterized in that making granule, tablet, capsule, suppository and membrane, gel, ointment, solution, suspensoid and Emulsion by adding various conventional pharmaceutic adjuvants.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410036061 CN1634118A (en) | 2004-11-05 | 2004-11-05 | Antivirus formulation containing polysaccharide polyanion zinc salt and its preparing process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410036061 CN1634118A (en) | 2004-11-05 | 2004-11-05 | Antivirus formulation containing polysaccharide polyanion zinc salt and its preparing process |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1634118A true CN1634118A (en) | 2005-07-06 |
Family
ID=34845763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410036061 Pending CN1634118A (en) | 2004-11-05 | 2004-11-05 | Antivirus formulation containing polysaccharide polyanion zinc salt and its preparing process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1634118A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100355790C (en) * | 2005-11-04 | 2007-12-19 | 山东福瑞达生物化工有限公司 | Method for preparing transparent zinc hyaluronic acid |
| WO2008033155A1 (en) * | 2006-09-15 | 2008-03-20 | Auriga Laboratories, Inc. | Kits for prevention and treatment of rhinitis |
| CN102973856A (en) * | 2012-11-14 | 2013-03-20 | 蚌埠丰原涂山制药有限公司 | Anti-cold pharmaceutical composition and preparation method thereof |
| CN103127125A (en) * | 2013-02-19 | 2013-06-05 | 青岛正大海尔制药有限公司 | Paracetamol and caffeine dry suspension and preparation method thereof |
| CN103694049A (en) * | 2013-12-20 | 2014-04-02 | 广西大学 | Plant protection product |
| CN101467988B (en) * | 2007-12-27 | 2014-07-09 | 北京德众万全医药科技有限公司 | Medicament composition containing paracetamol and pseudoephedrine hydrochloride and preparation method thereof |
-
2004
- 2004-11-05 CN CN 200410036061 patent/CN1634118A/en active Pending
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100355790C (en) * | 2005-11-04 | 2007-12-19 | 山东福瑞达生物化工有限公司 | Method for preparing transparent zinc hyaluronic acid |
| WO2008033155A1 (en) * | 2006-09-15 | 2008-03-20 | Auriga Laboratories, Inc. | Kits for prevention and treatment of rhinitis |
| CN101467988B (en) * | 2007-12-27 | 2014-07-09 | 北京德众万全医药科技有限公司 | Medicament composition containing paracetamol and pseudoephedrine hydrochloride and preparation method thereof |
| CN102973856A (en) * | 2012-11-14 | 2013-03-20 | 蚌埠丰原涂山制药有限公司 | Anti-cold pharmaceutical composition and preparation method thereof |
| CN102973856B (en) * | 2012-11-14 | 2014-12-03 | 蚌埠丰原涂山制药有限公司 | Anti-cold pharmaceutical composition and preparation method thereof |
| CN103127125A (en) * | 2013-02-19 | 2013-06-05 | 青岛正大海尔制药有限公司 | Paracetamol and caffeine dry suspension and preparation method thereof |
| CN103127125B (en) * | 2013-02-19 | 2014-08-20 | 青岛正大海尔制药有限公司 | Paracetamol and caffeine dry suspension and preparation method thereof |
| CN103694049A (en) * | 2013-12-20 | 2014-04-02 | 广西大学 | Plant protection product |
| CN103694049B (en) * | 2013-12-20 | 2018-06-19 | 广西大学 | A kind of plant protection product |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2019155389A1 (en) | An aqueous mucoadhesive and bioadhesive composition for the treatment | |
| CN1899505A (en) | Medicine composition for clearing heat and purging-fire | |
| CN101062289A (en) | External application medicine combination for treating gout | |
| CN1634118A (en) | Antivirus formulation containing polysaccharide polyanion zinc salt and its preparing process | |
| CN101077356A (en) | Application for polysaccharide extraction of grateloupia filicina in preparing antitumor medicine and other medicines | |
| CN1927293A (en) | Chinese medicine composition for treating skin burn and scald | |
| CN1666992A (en) | Medical use of catalpol and its homologs | |
| CN1434052A (en) | Cranesbill total flavonoid extract and use in preparation of anti-virus medicine | |
| CN1833693A (en) | Red medicine gel for treating traumatic injury and its prepn. method | |
| CN1833715A (en) | Skin care gel for skin titillation and prepn. thereof | |
| CN1943734A (en) | A Chinese traditional medicine for clearing away heat and toxic material | |
| JP5624367B2 (en) | Loxoprofen-containing pharmaceutical preparation | |
| CN1965893A (en) | Liquid formulation for treating allergic rhinitis | |
| CN1883620A (en) | Gel agent for treating superficial mycotic infection and method for preparing same | |
| CN1310647C (en) | Anti-cold medicine soft capsule and its preparing method | |
| CN1163227C (en) | Application of tanhin polyphenolic B magnesium in preparing medicine for treating chronic hepatosis | |
| CN1468601A (en) | Picroside-II as one new medicine for preventing and treating allergic and inflammatory diseases | |
| CN1278709C (en) | Medicine for treating cold and its preparing process | |
| CN101066425A (en) | Chinese medicine prepn for treating ungual mycosis | |
| CN1911293A (en) | Gel agent-Guzhining for treating osteoporosis and its prepn. method | |
| CN1679861A (en) | Medicine for treating toothache | |
| CN108785496A (en) | A kind of canker sore sustained release pad pasting and preparation method thereof | |
| EP3129031B1 (en) | Composition for treating stomach pain | |
| CN1698841A (en) | Medical usage of picrorhiza rhizome total glycoside extract | |
| CN1282479C (en) | Slowly-released traditional Chinese medicine adhering tablet for treating mouth mucous diseases and its prepn. method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |